Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified <scp>ALCAM</scp> as marker of resistance in castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer

Published:2022-06-21 Issue:8 Volume:151 Page:1405-1419
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Csizmarik Anita¹^ORCID,Keresztes Dávid¹^ORCID,Nagy Nikolett¹,Bracht Thilo²³⁴,Sitek Barbara²³⁴,Witzke Kathrin²⁴,Puhr Martin⁵,Tornyi Ilona⁶,Lázár József⁷,Takács László⁶⁷,Kramer Gero⁸,Sevcenco Sabina⁸,Maj‐Hes Agnieszka⁸,Jurányi Zsolt⁹,Hadaschik Boris¹⁰,Nyirády Péter¹,Szarvas Tibor¹¹⁰^ORCID

Affiliation:

1. Department of Urology Semmelweis University Budapest, Hungary

2. Medizinisches Proteom Center Ruhr University Bochum Bochum Germany

3. Department of Anesthesia, Intensive Care Medicine and Pain Therapy University Hospital Knappschaftskrankenhaus Bochum Bochum Germany

4. Center for Protein Diagnostics, Medical Proteome Analysis Ruhr‐University Bochum Bochum Germany

5. Department of Urology Medical University of Innsbruck Innsbruck Austria

6. Department of Human Genetics University of Debrecen Debrecen Hungary

7. Biosystems International Kft Debrecen Hungary

8. Department of Urology Medical University of Vienna Vienna Austria

9. Department of Radiobiology and Diagnostic Onco‐Cytogenetics, Center of Radiotherapy National Institute of Oncology Budapest Hungary

10. Department of Urology University Hospital Essen, University of Duisburg‐Essen Essen Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34159

Reference48 articles.

1. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

2. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

3. Abiraterone and Increased Survival in Metastatic Prostate Cancer

4. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

5. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The functions and regulatory pathways of S100A8/A9 and its receptors in cancers;Frontiers in Pharmacology;2023-08-28

2. Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2023-08-26